Donia M. El-Shafey, Mona Fadel Mohamed, Maha EI-Baz And Mohamed Adel Ezzat,

Objectives: The Aim Of This Clinical Study Was To Evaluate The Marginal Integrity Of Hydroxyapatite Nanofiber Reinforced Flowable Composite (NoVaPrO? Flow) Compared To A Conventional Resin-based Flowable Composite (Filtek? Z350 XT) During Management Of Initial Carious Lesion In Adult Population Over A One Year Period.

Materials and Methods: A Total Of 26 Volunteer Patients Who Fulfilled The Inclusion Criteria Were Selected To Participate In The Study, With Non-cavitated Initial Occlusal Carious Lesion Were Selected For This Randomized Split-mouth Clinical Trial. A Total Of 52 Sealants Were Placed, In Which Each Patient Had The Two Types Of Flow Able Composite; N OVaPro? Flow (Rl) Was Placed In One Side While Filtek? Z350 XT (R2) Was Placed On The Contralateral Side. Each Sealant Was Independently Evaluated In Terms Of Marginal Integrity After One Week, And Twelve Months Using FDI Criteria With FDIprob.

Results: After One Week, Both Sealants (Rl) And (R2) Had A Score Of (1) (100%). Any Other Score (2, 3,4, Or 5) Wasn"t Detected At The First Follow Up Interval (0%). After One Year, Score (1) Decreased To (73.1%) In (Rl) While (R2) Decreased To (57.7%), Both Sealants Showed Equal Percentage Of Score (2) (19.2%) While Score (3) Was Higher In (R2) (11.5%) Than (Rl) (7.7%), And Score (5) Was Only Detected In (R2) (11.5%), But There Was No Significant Difference In The FDI Grading In Both Sealants During Both Follow-up Intervals (P>O.05). Conclusion: Although The Clinical Performance Of Hydroxyapatite Nanofiber Reinforced Flow Able Resin Composite Was Better For Marginal Integrity Compared To The Conventional Nanofill Flow Able Resin Composite After One Year Of Follow Up, This Difference Was Not Statistically Significant.